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Summary 
Leishmaniasis is a disease caused by infection with the protozoan parasite Leishmania which 
is responsible for three main types of disease; cutaneous leishmaniasis, visceral leishmaniasis 
and mucocutaneous leishmaniasis which is related to the tissue tropism of the infecting 
species.   This presents a major challenge to successful drug treatment, as a drug must not 
only UHDFK DQWLOHLVKPDQLDO FRQFHQWUDWLRQV LQ LQIHFWHG PDFURSKDJHV WKH SDUDVLWHV¶ KRVW FHOO
but also reach infected cells in locations specific to the type of disease.  In this paper we 
discuss how studies using Leishmania have contributed to our knowledge on how drug 
delivery systems can be used to improve drug efficacy and delivery.  
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Introduction 
Leishmaniasis is a disease caused by infection with the protozoan parasite Leishmania, which 
is transmitted by female sandflies. The type of disease caused by the parasite depends on the 
LQIHFWLQJVSHFLHVDQGWKHKRVW¶VLPPXQHresponse [1] but three main forms occur; cutaneous 
leishmaniasis (CL), mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL,  
Table 1). The World Health Organisation estimates that 350 million people, living in 98 
countries, are at risk of contracting leishmaniasis, and each year approximately 1.5 million 
new cases of cutaneous and 500,000 of VL are reported. In terms of disease burden, 
leishmaniasis is responsible for 2,357,000 DALYs (Disability-Adjusted Life Years) lost due 
to ill effects caused by the disease.  
Table 1 The main species responsible for leishmaniasis, their geographical distribution and 
site of the parasites within the body.  
Type of 
leishmaniasis 
Main Species  Geographic Region Tissue Tropism 
Visceral 
L. donovani, L. 
infantum, L. chagasi 
India, Nepal, Sudan, 
Brazil, Ethiopia 
Disseminated in 
liver, spleen and 
bone marrow 
Cutaneous 
L. major, L. tropica, 
L. mexicana 
Brazil, Colombia, 
Afghanistan, Iran, 
Saudi Arabia and 
Syria 
Lesions form at the 
site of infected bite 
Mucocutaneous L. braziliensis 
Brazil, Bolivia, Peru, 
Ethiopia 
Mucosal tissue of 
mouth and nose 
 
The Leishmania parasite has two distinct morphological forms in its life cycle, the 
intracellular amastigote in the mammalian host and the extracellular promastigote, which is 
transmitted by a sand fly vector.  Infective promastigotes are deposited into the skin when an 
infected sand fly feeds. The promastigotes are taken up by phagocytes in the vicinity and 
transform into amastigotes within the parasitophorous vacuole. Over a period of 4-6 days, the 
amastigotes multiply inside the macrophage until its maximum capacity is reached and then 
the macrophage ruptures, releasing amastigotes which can infect new macrophages. The 
ability to control the infection depends on stimulating a protective immune response in the 
host. 7KLV XOWLPDWHO\ UHVXOWV LQ DFWLYDWLRQ RI WKH FHOO¶V F\WRWR[LF PHFKDQLVPV, usually 
involving the production of reactive oxygen and nitrogen intermediates. Details on the 
specific responses involved, which vary between species, can be found in recent reviews [2, 
3, 4].  The SDUDVLWH¶Vlife cycle is completed when an uninfected sand fly takes a blood meal 
from the infected host.    
Currently there is no vaccine to prevent leishmaniasis in people therefore disease control 
depends on treating infected individuals or programmes which target the vector e.g. use of 
insecticide impregnated bed nets), vector control or the reservoir host e.g. the dog for VL.  At 
present there are a limited number of drugs used in the treatment of leishmaniasis (Table 2) 
and many of the drugs are only suitable for use in certain geographical areas.  For example, 
antimonials were the first line treatment for the majority of Leishmania infections for over 50 
years but their use in treating VL is now limited due to the increasing incidence of drug 
resistance and relapse in endemic regions such as India and Nepal [5,6].  The introduction of 
miltefosine (MILT) for the treatment of VL was a major step forward as it was the first orally 
active drug.  However there are already problems with a reduction in treatment efficacy, 
which could indicate that drug resistance is being introduced into the parasite population, 
possibly due to incorrect dosing by individuals [7].  Amphotericin B (AMB) is now the first 
line treatment for VL but it requires administration via the parenteral route and its use is 
limited by its inherent toxicity and high cost [2]. Although AMB resistance has been induced 
in laboratory strains [8], there is no evidence that it is present in field strains (9).  
Leishmaniasis is mainly a disease of the poor and so development of new drugs does not 
elicit the same interest for drug companies as other diseases. There is however a willingness 
to co-operate in providing drugs for leishmaniasis as the recent "London Declaration on 
1HJOHFWHG 7URSLFDO 'LVHDVHV´ UHFHQWO\ VKRZHG 
(http://www.who.int/neglected_diseases/London_Declaration_NTDs.pdf). One way to 
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improve drug treatment would be to use a drug delivery system to increase the efficacy of 
novel or existing drug.  In this review we will discuss the variety of drug delivery systems 
that have been tested and demonstrate how studies on leishmaniasis have added to our 
knowledge on drug delivery.   
Table 2 Drugs used in the treatment of leishmaniasis. 
Drug Route  Dose 
Adverse side effects 
reported  
Pentavalent 
antimonials 
Intravenous/ 
Intramuscular 
20 mgSbV/kg for 28 
daysa 
Vomiting and 
nausea. Widespread 
resistance 
Pentamidine 
Intravenous/ 
Intramuscular 
4 mg/kg for 15 days 
alternative daysb 
Diabetes side effects 
Paromomycin Intramuscular 
 
15 or 20 mg/kg for 
21 daysc  
Renal Toxicity, 
Ototoxicity 
 
Miltefosine 
 
Oral 
 
2.5 mg/kg for 28 
daysd 
 
Poor compliance. 
Teratogenic 
Amphotericin B Intravenous 
 
 
 
15 mg/kg for 30 days 
on alternative days, 
or 20 mg/kg/day for 
20 dayse  
 
 
High costs. 
Nephrotoxicity 
Sitamaquine Oral 
1.75, 2, 2.5 or 3 
mg/kg/day for 28 
daysf 
Abdominal pain, 
potential renal 
toxicity 
The specific treatment regimen can vary for different Leishmania spp and their geographical 
location.  Dosing regimens are shown from specific studies as an indication of treatment 
protocols used [a10; b11; c12; d13; e14, f15] 
 
Drug delivery systems 
The niche in which the Leishmania lives presents challenges to drug delivery, as the drug has 
to achieve antiparasitic levels in multiple sites and the specific area targeted depends on the 
species of Leishmania.  For example in VL a drug must target parasites within macrophages 
in the spleen, liver and bone marrow, whereas in CL the drug must reach parasites in the 
cutaneous lesion(s).  Thus a drug must cross multiple membranes to reach the intracellular 
amastigote (Fig. 1) as the parasite is located within the parasitophorous vacuole within the 
macrophage. Imaging studies have shown the dynamic nature of these vacuoles and 
information on their biogenesis and during infection (16). These technical developments will 
aid in characterising delivery to the parasites within the parasitophorous vacuole but drug 
delivery to the Leishmania parasite still presents technical difficulties. Most analytical 
methods for drugs are based on high performance liquid chromatography and assessment of 
delivery to the parasite would require isolation of amastigotes, which may cause drug loss, 
and an assay method of a suitable sensitivity level to detect the drug present. Therefore most 
studies use reduction in parasite burdens as a measure of successful drug delivery.  In most in 
vivo studies traditional pharmacokinetic parameters (e.g. distribution phase half-life; 
elimination phase half-life; area under the plasma concentration-time curve; volume of 
distribution, total body clearance) and drug levels at the targeted site are used to assess drug 
delivery. For example, antimonial drugs given by the intravenous route are only present in the 
blood for a short period of time as they have a short half life (absorption phase mean half-life 
of 0.85 h) and a rapid clearance (elimination mean half-life of 2.02 h, 17), which would limit 
their uptake by the host cells and explain why multiple dosing is required for  parasiticidal 
levels to reach the Leishmania parasites. Recent reviews discuss the problems associated with 
delivery of drugs using different routes of administration (18, 19, 20), the problems 
associated with drug delivery to specific sites or organelles within the body (20, 21) and drug 
deposition and uptake at these sites (21, 22). A drug delivery system can help achieve this 
aim as it directs more of the drug dose to tissues and away from the systemic circulation. 
Once the drug formulation has accessed cells at the site of uptake then the inherent 
pharmacokinetic properties of the drug within the formulation will influence its release into 
surrounding tissues (23, 24).  Most drug delivery systems act as drug depots that decrease the 
release rate of the incorporated drug and therefore give more time for the drug to concentrate 
within the targeted cells.  Macrophages, which are found in high concentrations in a number 
of locations in the body e.g. liver, lungs, spleen, play an important role in enhancing tissue 
uptake of particulate nanoformulations.  Macrophages phagocytose particles from their 
immediate vicinity as part of their innate immune response and as a consequence act as a 
local drug depot. This means that the drug is directed directly to the Leishmania parasite in 
infected macrophages (25, 26, 27). Borborema et al., 2011, demonstrated the advantages of 
this type of approach using a liposomal formulation of meglumine antimoniate They showed 
that using the carrier system reduced the 50% inhibitory concentration (IC50 value) value 
against the intracellular amastigote stage of L. major compared to the drug solution, from 93 
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µM to 10.5 µM. Moreover, they also showed and that infected macrophages were more 
efficient than uninfected macrophages at taking up the liposomes (28).  A drug delivery 
system can facilitate a reduction in the total drug dose and/or number of doses required, 
which is particularly important for a potentially toxic drug. For example, amphotericin B 
(AMB) that is associated with nephrotoxicity. This can be important for a drug that causes 
nephrotoxicity such as amphotericin B (AMB). This beneficial feature for drug delivery 
systems has been clearly demonstrated by the higher efficacy and lower toxicity of lipid 
formulations of AMB compared to AMB solution  [29].  However these lipid formulations 
are prohibitively expensive for widespread use in endemic countries. This problem is being 
addressed by a World Health Organisation (WHO) initiative, which facilitated the donation 
of 445,000 vials of AMBisome for the treatment of VL.  
Repurposing drugs originally designed for other clinical conditions gave new  antileishmanial 
treatments.  Thus AMB was originally developed for the treatment of fungal infections and 
MILT was originally in development for the treatment of cancer. Repurposing clinically 
approved drugs for treatment of leishmaniasis is an attractive approach as the majority of the 
required toxicity testing has already been completed, although additional testing would be 
required if a different mode of administration is used.  Endemic countries often have 
traditional medicines that have been used for the treatment of leishmianiasis, and 
development of novel drugs from plant products has been investigated (30).  
Intravenous delivery 
The parenteral route is used for the majority of antileishmanial drugs as it ensures distribution 
of the drug to all sites of infection, however it also exposes non-target organs, which is 
particularly important for potentially toxic drugs. This route of administration has been used 
extensively in studies using a variety of drug delivery systems including liposomes, non-ionic 
surfactant vesicles (NIV), nanocapsule emulsions, nanodiscs and nanoparticles. Intravenous 
drug delivery has been very successful for treating visceral leishmaniasis as the liver and 
spleen, which are rich in macrophages, are the main organs for clearing particulates from the 
systemic circulation and the main sites of infection.  Early studies by Abra and Hunt in a 
series of studies using radio-labelled liposomes showed that they delivered effectively 
increased delivery to the liver and spleen, and that dose, size and dosing regimen influenced 
delivery (31, 32, 33)  
 
Liposomes are synthetic vesicles, prepared using phospholipids that form a natural bilayer. 
The exact composition of liposomes can vary and often includes phosphatidylcholine (PC) 
and cholesterol. By assembling the liposomes in conjunction with an aqueous solution, the 
compound is encapsulated in the inner core of the lipid bilayer. When the liposome comes in 
to contact with a cell membrane it may fuse with  itor be taken up by phagocytosis, thus 
delivering the drug solution inside the cell. Vesicle characteristics such as composition, size, 
surface charge and drug loading all have important influences on drug delivery (31, 32) 
Roychoudhury et al. (34) prepared liposomes containing sodium stibogluconate (SSG) from 
PC and stearlyamine (PC-SA) or PC and cholesterol (PC-Chol) using sonication followed by 
centrifugation at 60,000 x g to remove unentrapped drug, a method that would not adapt well 
to large-scale manufacture and has been shown to damage the vesicle bilayer (35). Single-
dose treatment of mice infected with L. donovani strains that had different inherent 
susceptibilities to SSG with PC-SA liposomes containing SSG (PC-SA-SSG, 12 mg Sbv/kg) 
resulted in a significant reduction in liver, splenic and bone marrow parasite burdens (>84%) 
whereas similar treatment with PC-Chol liposomes containing SSG (PC-Chol-SSG) only 
caused a significant reduction in liver parasite burdens. The advantage of using a carrier 
system was clearly demonstrated in this study as similar treatment with SSG solution at a 
dose of 300 mg Sbv/kg only significantly affected liver parasite burdens in mice infected with 
a SSG susceptible strain. Drug uptake studies in parasites showed that significantly higher 
levels of Sb were present in amastigotes recovered from infected macrophages treated with 
PC-SA-SSG compared with PC-Chol-SSG or SSG solution. The entrapment efficiencies 
quoted for the two formulations were similar, indicating that both type of carriers would 
deliver a similar amount of drug to cells, therefore different in drug delivery may reflect 
differences in the rate uptake for the two type of liposomes (36). PC can interact with 
phosphatidylserine (PS) residues present on the cell membranes and this could improve 
uptake of PC-SA liposomes [37].  
We have shown that non-ionic surfactant vesicles (NIV), which are analogous to liposomes, 
but contain a non-ionic surfactant instead of a phospholipid, are very effective at delivering 
various antileishmanial drugs (SSG, amphotericin B and paromomycin) in rodent and canine 
models of visceral leishmaniasis [38, 38, 40, 41].  The enhanced activity compared to drug 
solution alone was associated with the ability to favourable alter the in vivo pharmacokinetics 
of the drug.  For example, treatment of dogs with SSG-NIV prevented the rapid elimination 
phase associated with free SSG treatment, resulting in significantly higher antimony levels in 
the liver and spleen (39). Similar treatment with SSG-NIV had no adverse effect on lesion 
development in L. major infected mice (unpublished data), probably because the formulation 
did not target the drug to the skin parasites.  More recent studies clearly demonstrated this 
effect. Iintravenous treatment with a NIV formulation containing luciferin did not enhance 
delivery of luciferin to luciferase-expressing L. major parasites within the footpad of a 
mouse, but did enhance delivery of the substrate to luciferase-expressing L. donovani 
parasites located within the liver of a co-infected mouse (Fig. 2).  
Kansal et al. [42] showed that a nanocapsule emulsion (NC) containing doxorubicin (NC-
DOX) had a 1.75 fold higher uptake if PS was anchored on to its surface compared to non-PS 
containing NC-DOX.  The high drug levels within amastigotes after PC-SA-SSG compared 
to PC-Chol-SSG treatment could be related to lower inhibition of macrophage function, a 
factor that could be explored by infecting macrophages using different parasite: macrophage 
ratios and determining the effect on SSG uptake.  
Modifying the surface of the delivery vehicle to increase the time it remains in the systemic 
circulation or by incorporating molecules, which target surface receptors on the target cell, 
can increase the efficacy of a drug formulation.  This has been exploited by incorporation of 
polyethylene glycol (PEG) into liposomes to produce µORQJFLUFXODWLQJ¶RUµVWHDOWK¶OLSRVRPHV
that are more likely to be taken up by tissues [43]. Integrating dendrimers, which interact 
with MHC class II molecules, into amphotericin B liposomes increased their uptake by 
phagocytic cells and intravenous treatment of L. major infected mice with this formulation 
was more effective at treating skin lesions compared to liposomal AMB alone. Interaction 
with MHC class II molecules was confirmed to be important as incorporation of a dendrimer 
that targeted a random peptide did not increase the efficacy of liposomal AMB [44] An 
unexpected side effect of this formulation was its ability to boost host immune responses, 
leading to enhanced interferon gamma production by L. major specific splenocytes. Infection 
with Leishmania suppresses immune responses in susceptible individuals both at the local 
(i.e. infected macrophage) and whole body level, so production of an immunotherapeutic 
drug formulation would be ideal for leishmaniasis [45]. 
This combined immunotherapeutic approach was recently tested using a liposomal 
formulation of resiquimod [46], a derivative of imiquimod, which is an FDA-approved Toll-
like receptor 7/8 agonist, and also has FDA approval for cutaneous use. Resiquimod 
liposomes were prepared by dissolving the formulation constituents in methanol/chloroform 
mix, rotary evaporation was then used to remove the solvents and drug loaded liposomes 
were formed by hydration with water.  Freeze-thaw cycles were used, presumably to improve 
drug entrapment as a reduction in size was achieved by passing the liposome suspension 
through an extruder fitted with an 80 nm polycarbonate membrane.  Unentrapped drug was 
removed from the resulting suspension by passing down a PD-10 column and the liposomes 
were lyophilised in the presence of sucrose as the cryoprotector.  On reconstitution, 
liposomes with a mean vesicle size of 75 ± 31 nm and an entrapment efficiency of 7% was 
obtained.  Intravenous treatment with a single dose of resiquimod liposomes (0.38 mg/kg, 
assuming a 20 g mouse weight) caused a significant reduction in splenic, liver and bone 
marrow L. donovani parasites compared to treatment with the carrier alone but the drug 
formulation was not as effective as single dose treatment with SSG (500 Sbv/kg). 
Determination of host immune responses showed that resiquimod liposome treatment was 
associated with enhanced interferon gamma (IFN-J) and interleukin 10 (IL-10) production by 
splenocytes activated with specific antigen compared to control or carrier alone groups.  
These two cytokines act antagonistically as IFN-Jproduction stimulates macrophages to kill 
Leishmania and is associated with protection against L. dovovani infection whereas IL-10 
suppresses macrophage activation and its production is associated with susceptibility [47]. 
However the relative local concentration of each cytokine at the site of infection will be 
important in determining whether the immunostimulatory effects aid parasite clearance or 
not.  
Nanodiscs or nanodisks (ND) are structurally similar drug carriers to liposomes and have a 
phospholipid bilayer integrated with apolipoprotein [48].  They are typically less than 200 nm 
in size have a hydrophobic core instead of an aqueous core, which is surrounded by 
apolipoprotein. This is beneficial from a drug delivery point of view as the ND are soluble in 
the aqueous conditions of the bloodstream [49].  For this reason, ND are have been used to 
solubilise and improve the delivery of the relatively insoluble AMB. In a murine model of 
cutaneous leishmaniasis, intravenous treatment with four doses of AMB-ND (5mg/kg, days 4, 
7, 14 and 21) completely cleared L. major parasites and lesions in BALB/c mice. Treatment 
with a comparable dose of liposomal AMB (AMBisome) reduced parasite burden and lesion 
size but did not achieve cure. Moreover, there was no appreciable change in cytokine levels 
in the AMB-ND treated mice which indicates that the clearance was not associated with a T 
helper cell response switch and suggests that a nanodisc based AMB treatment could be 
suitable for immunocompromised patients [50].  The superior efficacy of the ND could be 
related to the way AMB is incorporated into the ND. AMB causes ND bilayer interdigitation 
and in treated Leishmania cells there would be a reduction in bilayer thickness of the 
host/parasite membrane bilayer, so that only 1 AMB molecule spans the membrane bilayer, 
and as AMB molecules self-associate, a pore formed from 8-12 AMB would form.  This pore 
results in leakage in the target cell membrane resulting in death of the  host cell/parasite cell 
[51].  
Conjugating drugs to polymeric nanoparticles is another strategy used to deliver drugs to 
particular target sites.  Polymeric nanoparticles have an advantage over lipid formulations as 
their production costs are usually lower and the shelf life at room temperature is extended 
[52].  Gaspar et al. [53] and Paul et al. [54] showed that polyalkylcyanoacrylate (PACA) 
primaquine or polymethacrylate (PMMA) pentamidine nanoparticles respectively could be 
used to enhance drug delivery. Poly(lactide-co-glycolide) (PLGA) nanoparticles have been 
used to improve the delivery of AMB in a number of studies.  For example, Nahar and Jain 
[55] produced PLGA nanoparticles conjugated to AMB (AMB-NP) which had a size of less 
than 200 nm and a polydispersity index (PDI) below 0.16. Additionally, inclusion of PEG to 
couple PGLA to mannose improved their uptake by macrophages and efficacy against L. 
donovani ex vivo amastigotes. An in vitro study showed that saponin loaded PLGA-
nanoparticles were active against axenic and ex vivo amastigotes of L. infantum and confocal 
microscopy allowed visualisation of saponin-loaded nanoparticles uptake by L. donovani 
infected macrophages [56]. The same group recently characterised the delivery of AMB- 
PLGA nanoparticles against L. infantum parasites and several fungal species a showed that 
the formulation was was either equivalent or more efficacious than AMBisome or Fungizone 
against promastigotes and amastigotes [57]. 
Non-invasive drug delivery 
Ideally, any new drug formulation developed for the treatment of leishmaniaisis should be 
administered by a non-invasive route as it removes the requirement for hospitalisation, 
improves patient compliance and removes other risks e.g. occupational risk of infection or 
environmental hazards associated with disposal of contaminated sharps.  There are a number 
of routes that can be used [58] but the three that are probably most relevant for leishmaniasis 
are oral, pulmonary and topical.    
Oral delivery is the preferred method for patients and clinicians, as it does not require 
hospitalization of the patient.  Developing oral formulations of current chemotherapy options 
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is attractive as it can help reduce the effective dose required, helping to reduce both side 
effects and the cost of treatment. However this route offers its own challenges as the 
gastrointestinal tract provides harsh physicochemical conditions.  In addition any drug taken 
up in the gut has to undergo first pass metabolism in the liver, where it is exposed to enzymes 
[59]. Although patient compliance is higher for oral formulations, a lack of treatment 
supervision can lead to patients not completing the full course of treatment.  This is a major 
issue as it may facilitate the development of drug resistance in Leishmania. MILT is the only 
oral drug used in the clinical treatment of leishmaniasis and it was originally developed as an 
anticancer agent. It is highly effective against VL, giving cure rates of 94%.  But recent 
evidence in India indicates that relapse rates are now higher, even though there was no 
apparent increase in MILT resistance in parasites isolated from VL patients before, and after, 
treatment.  Parasites isolated from post dermal kala patients do exhibit increased resistance to 
MILT [60] and in Nepal the number of VL patients are not responding to MILT treatment is 
increasing [61].   
 
Imipramine, clinically used to treat treat depression by the oral route, has recently been 
shown to be effective against L. donovani.  Repurposing drugs for other clinical indications 
has been suggested for a some time [62] but it is likely to require public funding for 
leishmaniasis.  
 
A number of different delivery systems have been used to formulate oral drug formulations 
[63] and in leishmaniasis the main drug used in studies is AMB as it can also be used to treat 
fungal infections. AmB is poorly soluble and susceptible to degradation in the gut. As such, 
parental administration is necessary. An oral formulation stabilising AmB and improving 
solubility would be beneficial. A 5-day oral treatment protocol using carbon nanotubes 
covalently linked to AMB (f-CNT-AMB) at a dose of 15 mg AMB/kg/day resulted in a 98% 
reduction in splenic parasite burdens in L. donovani infected hamsters [64]. Previous studies 
had shown that the f-CNT carrier alone had antileishmanial activity, although the 
intraperitoneal route was used in the original study.  It was suggested that induction of host 
immunity rather than induced cytotoxicity was responsible for the antileishmanial activity as 
a slight inflammatory response was noted at the injection site in mice.  In vivo studies showed 
that the carrier did not affect creatine or alkaline phosphatase, sodium glucose phosphatase 
levels, markers associated with toxicity [65]. The f-CNT-AMB formulation was stable six 
month after storage at room temperate but further studies are intended to improve the 
formulation. Studies using Caco-2 cell monolayers have shown that f-CNT can cause 
reversible modulate tight junction formation, which would be required for transport across 
the gut epithelial barrier. In addition f-CNT had the ability to down regulate the activity of P 
glycoprotein efflux activity, which would help to increase the bioavailability of any drug 
incorporated into the carrier system [66]. CNT have also been shown to activate reactive 
oxygen species but this activity was associated with cytotoxicity in treated keratinocytes [67], 
so may not be important in the improved f-CNT formulations.  
Nanoemulsions are mixtures of two normally immiscible liquids that are usually stabilised by 
using a surfactant, which can form a polymer shell around the outside of the emulsion to 
prevent coalescence. Formulating the emulsion as oil-in-water allows the solubilisation of 
poorly aqueous soluble drugs, such as AMB, and protects them from degradation. The first 
example of this formulation for treatment of VL was reported in 2004 [68]. IC0-010, a lipid 
emulsion formulation of AMB currently being developed by iCo-therapeutics, was granted 
orphan drug status by the US Food and Drug Administration [69]. The formulation contains a 
mono- and di-glycerides and d-Į-tocopheryl polyethylene glycol succinate, which form a 
self-emulsifying structure that forms droplets in intestinal conditions at 37°C. The 
formulation has been shown to be highly effective in a murine model of VL and is stable at 
temperatures expected in tropical environments.  Less developed formulations of AMB have 
been produced by other researchers.  For example, a nanoparticle formulation of AMB was 
shown to be more effective that Fungizone in a murine model of VL but further work is 
required to improve its in vivo activity [70].  
Although pulmonary delivery is used mainly as a non-invasive route to target drugs directly 
to the lungs it has also been used to deliver drug systemically as the lung epithelium is very 
close to the blood circulation. Drug formulations are aerosolised, normally using an 
inhaler/nebuliser. The aerosol droplet size has a major influence on deposition of the inhaled 
drug formulation within the lungs.  Ideally droplets need to have a mass median aerodynamic 
diameter (MMAD) of 0.5-5 µm [71, 72, 73]. If the droplets are too large they will not reach 
the aveoli as they are trapped in the upper airway and then swallowed as part of the normal 
lung clearance mechanisms, and if they are too small then the drug formulation would be 
removed from the lungs when the patient breathes out. There are a number of excellent 
reviews on type of nebulisers and factors affecting lung deposition. The mucus lining the 
lungs can impede the uptake of drug formulations and the presence of enzymes in lung lumen 
can lead to drug metabolism, which could inactivate the drug before its up take up by cells 
within the lung epithelium. The lungs have a larger macrophage population and these cells 
have a major role in taking up particulates. This means that nanocarriers are likely to be 
cleared by these cells, providing a deposition site for the drug, which would be released from 
the carrier at the site of uptake during phagocytosis. Imaging studies have shown that there is 
one resident macrophage for every three aveoli and that these cells remain sessile even when 
challenged with a bacterial pathogen,. This could indicate that these cells are unlikely in 
PRYHPHQWRID µLQWUDFHOOXODUGUXJGHSRW¶ WRDVLWHRI LQIHFWLRQWR IDYRXUORFDOGUXJGHOLYHU\
[74]. However dendritic cells are mobile and they could be responsible for trafficking drug to 
site of infection/local lymph nodes as part of their normal immune responses [75]. Technical 
difficulties make it difficult to determine if intact drug carriers access the systemic circulation 
after uptake in the lungs, therefore delivery of inhaled drug formulations to sites other the 
lungs is mainly based on determination of drug/label incorporated into the carrier system. 
This approach has been used in the treatment of lung conditions such as Invasive pulmonary 
aspergillosis (IPA).  For example prophylactic treatment of neutropenic patients with 
haemolytic disease with liposomal amphotericin B was tested. The study showed that 
treatment significantly reduced the incidence of IPA and prevented the renal toxicity 
associated with intravenous AMB treatment. Carter et al. [76] have shown that pulmonary 
route is not only suitable for lung conditions but it can also be used to target liver conditions. 
Thus treatment with a NIV formulation of AMB resulted in a significant reduction in liver 
parasite burdens in a murine model of VL and the same formulation was effective at reducing 
Aspergillus levels in the lungs. This route is unlikely to be suitable for deeper tissue sites as 
the formulation failed to significantly affect splenic and bone marrow parasite burdens in L, 
donovani infected mice and had no significant effect on lesion progression in mice infected 
with L. major.   Imaging studies indicated that the lack of effect was due to an inability to 
enhance delivery to the footpad of mice infected with luciferase-expressing L. major (Fig. 3).   
Topical treatment is particularly attractive for the treatment of CL as the drug is applied 
directly to the lesion, however, it may be less efficacious against VL.  The skin presents a 
formidable challenge to drug delivery as  it is adapted to prevent entry of potentially harmful 
agents [77]. One of the drugs commonly used in topical treatments for CL is the 
aminoglycoside PMM, which was first tested by El-On and colleagues LQ WKH ¶s [78].  
Studies using liposomal formulations of PMM indicated that the vesicle improved drug 
delivery into the skin but the levels achieved (5-7% of the applied dose) were still very low 
[79].  Another study using liposomal paromomycin had higher skin penetration (15% of the 
applied dose).  Four weeks treatment using liposomal PMM at 50mg/dose twice a day cured 
mice [80]. However it is possible that mice ingested some of the drug formulation as we have 
found that mice clean away any formulation applied to the skin, even if it contains 
denatonium benzoate, a compound used to deter ingestion [81].  
Future perspectives 
The ability to successful treat Leishmania depends on not only identifying an effective drug,  
it is also important to deliver that drug at parasiticidal levels into infected macrophages, 
which can reside at multiple sites within the body. Advances in non-invasive imaging 
techniques [82] and the production of novel Leishmania strains expressing reporter genes e.g. 
green fluorescent protein (GFP), cherry red fluorescent protein or luciferase [83], have 
allowed detailed studies on disease burdens and pharmacokinetic studies at both the cellular 
level and in individual animals.  Selection of the most appropriate label for experimental 
studies is essential.  For example, GFP-labelled parasites allow direct visualisation of 
parasites without requiring a substrate (luciferin), which could be more beneficial for in vitro 
assays, however,  for in vivo studies where parasites are located in deeper tissues rich in 
blood (e.g. the liver), then luciferase-expressing parasites may be more appropriate.  Tissues 
can absorb the light emitted by fluorescent dyes and light scattering can mean that a lot of the 
light does not reach the detector or does not indicate the correct localization of parasites.  
Bioluminescence gives a stronger signal but it is not without its problems. Luminescence 
depends on delivery of luciferin to luciferase-expressing cells. Luciferin has a large volume 
of distribution after the recommended intraperitoneal injection but a short in vivo half-life, 
meaning that imaging is usually carried out within 30 min of dosing. Bioluminescence is also 
dependent on the presence of oxygen, therefore there will be a lo/no signal if if hypoxia is 
present at the site of the luciferase-expressing cells.  The development of better gene reporter 
systems and continued development of imaging systems that allow integration of information 
from different types of imaging systems (e.g. fluorescence, bioluminescence, radioisotope 
imaging and X-ray-based computed tomography) means that a better understanding of the 
disease processes and treatment outcome is possible. It is now possible to have high 
throughput screening of compounds against the more clinically relevant intracellular 
amastigote stage of Leishmania rather than the promastigote stage [84] and it is possible to 
determine the effect of drug treatment on parasite burdens in multiple sites within the same 
animal at different times post-treatment, to get a better indication of how altering treatment 
regimens effects parasite numbers.  It is also possible to determine how effective a drug 
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delivery system is at delivering a drug to different sites in the body, allowing rational design 
a drug delivery system so its effect on its delivery capabilities can be assessed. We have 
shown that it is possible to monitor drug delivery to multiple sites within the same animal 
using this type of imaging technology (Fig. 2).  Eventually these types of studies will provide 
the data to mathematically model drug delivery so that the knowledge gained from other 
specialties e.g. fluid mechanics can be integrated so that it may eventually be possible to 
study in vivo drug delivery using very few animals and systems specific to the species being 
treated.  Researchers need to keep in mind scale up parameters of their formulations at the 
early stage of development and try and use constituents of pharmaceutical grade where 
possible.  Quite often experimental methods contain steps that are not practical for large-scale 
manufacture and considerations like these early on can save time further down the line.  All 
our formulation studies have suggested that drug loading is one of the most important 
parameters in formulation efficacy, a factor strongly influenced by drug solubility. Therefore, 
chemical modification of active compounds to increase their aqueous solubility is an 
important area of research. In addition any drug development programme must include 
screening against recently isolated field strains in their studies as it is possible that by the 
time the drug formulations have gone through clinical trials it may be inappropriate for use in 
endemic countries.  We developed a NIV formulation of sodium stibogluconate, which was 
effective a single intravenous dose in rodent VL models, but funding for this project stopped 
once it became apparent that antimony resistance was widespread in India.   There are 
number of studies determining the molecular basis for resistance to antileishmanial drugs as 
knowing how the mechanism may allow the development of novel therapies that can block 
the mechanism(s) and turn a clinically ineffective drug back into an effective treatment.  For 
example, resistance to PMM in L. donovani was related to increased membrane fluidity 
accompanied with decreased intracellular drug accumulation and was associated with 
increased expression of ATP-binding cassette (ABC) transporters (MDR1 & MRPA) [85] 
and the ABC transporter gene MRPA was amplified in antimony resistant field isolates of L. 
donovani [86].  ABC transporters also mediate drug resistance in cancer cells [87], therefore 
an understanding of how they operate in Leishmania is relevant to other clinical conditions.  
 
Leishmania PD\ EH D VSHFLHV WKDW LV D µQHJOHFWHG WURSLFDO GLVHDVH¶ EXW WKLV SDWKRJHQ FDQ
provide fundamental information on drug delivery that is relevant to diseases that reside in 
similar tissues/organs within the body.  Therefore funding research into this pathogen is easy 
to justify, even if it is a disease associated with poverty.  
 Executive summary 
x Leishmaniasis: current drugs used and their limitations  
x Drug delivery systems: the role of drug delivery systems in modifying drug delivery 
to the Leishmania parasite are discussed: including vesicles, nanocapsule, nanodiscs, 
nanoparticles, nanotubes, nanoemulsions  
x Intravenous delivery: novel drug formulations given by the intravenous route are 
discussed 
x non-invasive drug delivery: novel drug formulations given by the oral, pulmonary and 
cutaneous routes are discussed 
x Future perspectives: co-ordinating data obtained using new imaging technologies 
along with engineering disciplines such as fluid dynamics may aid in the design of 
better drug delivery system 
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Fig legends 
Fig. 1 The route a drug must take to access intracellular Leishmania amastigotes within 
macrophages.  A drug enters the body by the route administered and has to reach the sites 
where infected macrophages reside and as a consequence have to cross multiple membranes 
to enter the parasite (N is the nucleus of the cell).  
Fig. 2.  Imaging of mice and organs samples using the IVIS® inaging system.  Mice (A and 
B) were inoculated intravenously with 5 x 105 B16 F0 luc cells and 30 minutes later treated 
intravenously with luciferin solution (free, 3.38 mg/ml; 30 mg/kg) ) or luciferin-NIV (NIV, 
prepared using luciferin solution at 18.69 mg/ml and diluted 1:5 just before use; 30 mg/kg).  
Animals were imaged at 2 min intervals from 10 minutes after dosing.  The results for 14 (A) 
and 28 (B) minutes after dosing clearly show that using NIV improves delivery of luciferin to 
the cancer cells.  BALB/c mice were inoculated with 2 x 107 luciferase expressing L. 
donovani  and treated intravenously with luciferin solution (Free) or luciferin-NIV (NIV) 
using the protocol for  A and B.   30 minutes after treatment the mice were sacrificed and the 
liver and spleen of each animal removed.  The organs were imaged immediately after 
removal (C) or after immersion in luciferin solution (D, 150 µg/ml PBS pH 7.4) for 5 mins to 
allow comparison of the total parasite burdens present (D) in the spleen and liver and the 
parasite burdens exhibited by in vivo  treatment with the two luciferin formulations.  The 
results clearly show that using NIV improved delivery of luciferin to the parasites and 
maintained luciferin level longer than that achieved for luciferin solution.   Detailed methods 
are given in Alsaadi et al. [52]. 
 
